Literature DB >> 9303896

[Rationale for lipid therapy. Prevention or treatment of coronary heart disease?].

E Windler1, F U Beil.   

Abstract

Coronary artery disease has still a grave prognosis. More than half the patients die within 24 hours, mostly before reaching a hospital. A minority survives the first year. Only more intense prevention will change this. Primary prevention in a narrow sense refers to the prevention of the development of early lesions in the youth and as such is a responsibility of the education towards a healthy lifestyle. In our population a majority of middle-aged is likely to have developed arteriosclerosis, so that we deal only with clinically defined primary prevention even though they are asymptomatic. The outstanding effects of lipid therapy in patients at risk for coronary heart disease will primarily result from avoiding the development of instable plaques. Reduction of LDL-cholesterol and increase of HDL-cholesterol is most effective in patients with proven coronary artery disease. Evidently the majority of coronary events can be prevented by idealizing the lipid parameters. In contrast, the chronic coronary syndrome is the domain of the interventional cardiology. Lipid therapy will lead only gradually to a reduction of significant coronary stenoses. However, there is the still insufficiently investigated potential of improving the endothelial dysfunction by correcting the lipid metabolism to reduce angina.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303896     DOI: 10.1007/BF03044349

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  33 in total

1.  Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography.

Authors:  D Giroud; J M Li; P Urban; B Meier; W Rutishauer
Journal:  Am J Cardiol       Date:  1992-03-15       Impact factor: 2.778

Review 2.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

Authors:  V Fuster; L Badimon; J J Badimon; J H Chesebro
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

Review 3.  Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

Authors:  K Pyörälä; G De Backer; I Graham; P Poole-Wilson; D Wood
Journal:  Atherosclerosis       Date:  1994-10       Impact factor: 5.162

4.  Angiographic predictors of new coronary occlusions.

Authors:  M K Pétursson; E H Jónmundsson; A Brekkan; T Hardarson
Journal:  Am Heart J       Date:  1995-03       Impact factor: 4.749

5.  Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation.

Authors:  A Faggiotto; R Ross; L Harker
Journal:  Arteriosclerosis       Date:  1984 Jul-Aug

6.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators.

Authors:  A F Parisi; E D Folland; P Hartigan
Journal:  N Engl J Med       Date:  1992-01-02       Impact factor: 91.245

7.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.

Authors:  S Yusuf; D Zucker; P Peduzzi; L D Fisher; T Takaro; J W Kennedy; K Davis; T Killip; E Passamani; R Norris
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

8.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial.

Authors:  D Ornish; S E Brown; L W Scherwitz; J H Billings; W T Armstrong; T A Ports; S M McLanahan; R L Kirkeeide; R J Brand; K L Gould
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

9.  Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels.

Authors:  F M Sacks; J L Rouleau; L A Moye; M A Pfeffer; J W Warnica; J M Arnold; D T Nash; L E Brown; F Sestier; J Rutherford
Journal:  Am J Cardiol       Date:  1995-03-15       Impact factor: 2.778

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.